Mr. Stern has been involved in a variety of domestic and cross-border middle market valuation, capital raising and M&A transactions in the areas of healthcare services/healthcare IT, medical devices/products, and nutraceuticals/pharmaceuticals. Within healthcare services/HCIT, Mr. Stern has worked on some of the largest transactions in the long-term care sector, including the $1.4 billion acquisition of The Multicare Companies by Genesis Health Ventures, Texas Pacific Group and Cypress Group. He has also worked on the initial public offering for United Payors & United Providers (specialty managed care); the sale of Millennix (CRO) to IT&E International and The Comvest Group; and a follow-on offering for HBO & Co. (healthcare information systems) prior to its sale to McKesson. In medical products/life sciences, Mr. Stern has worked on financings for Innotech (ophthalmology devices) prior to its sale to J&J; ValveXchange (heart valves), Neurex (pain management) and Medgenics (protein therapeutics), as well as the merger of four publicly-traded companies into ICN Pharmaceuticals and the sale of Alan James Group (nutraceuticals) to Interleukin Genetics.
Mr. Stern is the leading investment banker in the fertility (IVF) sector, having closed numerous transactions including the sale of IGENOMIX, the merger of RMA of NJ and IVI of Spain, the sale of Advanced Fertility of Chicago to Prelude Fertility, the sale of Santa Monica Fertility to Webster Equity Partners, and the sale of InVia Fertility to In Vitro Sciences.